मैट्रिक्स
 
 
न्यूलैंड लेबोरेटरीज > कंपनी इतिहास > Pharmaceuticals > कंपनी इतिहास का न्यूलैंड लेबोरेटरीज - बीएसई: 524558, NSE: NEULANDLAB

न्यूलैंड लेबोरेटरीज

बीएसई: 524558  |  NSE: NEULANDLAB  |  ISIN: INE794A01010  |  Pharmaceuticals

कंपनी इतिहास - न्यूलैंड लेबोरेटरीज
Neuland Laboratories Limited, engaged in the manufacture of bulk drugs
 has been incorporated in 1984 as a private limited company.  The
 Company has been promoted by  Dr. D.R.Rao, Ph D. in Organic Chemistry
 from the University of Notre Dame, USA.  The company commenced
 operations in
 June 1986 at its plant at Bonthapally Village, Medak District, Andhra
 Pradesh with a capacity to manufacture 1.2 tonnes per annum (tpa) of
 Salbutamol sulphate, an anti asthmatic drug and its intermediates
 such as salbutamol base and bencyl salbutamol.
 
 In 1990 the Company expanded its installed capacity for salbutamol
 sulphate and its intermediates to 9 tpa.  In 1993, the Company
 completed a project for the manufacture of 2.4 tpa of terbutaline
 sulphate (Terbutaline), an anti asthmatic drug, 3.6 tpa of labetalol
 hydrochloride (Labetalol), an anti hypertension drug and for further
 expanding the capacity of salbutamol sulphate to 18 tpa. The Company
 commenced manufacturing ciprofloxacin by utilising part of the
 additional facilities created for salbutamol sulphate.  The total
 project cost of Rs.346 lacs was financed by a rupee term loan of
 Rs.260 lacs from ICICI and cash accruals of Rs.86 lacs.
 
 In 1994, the Company completed a project for further diversifying its
 bulk drug manufacture and set up a new plant at I.D.A. Pashamylaram,
 Medak district, Andhra Pradesh for the manufacture of 1.5 tpa of
 enalapril maleate (Enalapril), a cardio-vascular drug, 60 tpa of
 ranitidine hydrochloride (Ranitidine), an anti-ulcer drug and 66 tpa
 of Quinolones (such as Ciprofloxacin, Norfloxacin, Ofloxacin and
 Pefloxacin), a new generation of anti-bacterial drugs.  The project
 cost of Rs.1570 lacs was financed by rupee term loans of Rs.600 lacs
 (ICICI - 400, SCICI - 200), equity issue of Rs.870 lacs, state
 subsidy of Rs.15 lacs and cash accruals of Rs.85 lacs.  The
 commercial production commenced in October 1994.  Out of the equity
 of Rs.870 lacs, Rs.570 lacs was offered to the public (at a premium
 of Rs.35/- per share).  The issue was oversubscribed 70 times and the
 shares are listed on the
 Hyderabad and Bombay Stock Exchanges. 
 
 The Company has been granted quality system certification as per ISO
 9002-9004, for its Plant at Bonthapally Village, for the manufacture
 and supply of bulk drugs and intermediates.
 
 The Company has well equipped Research & Development facilities at
 Bonthapally which has been recognised by the Government of India. 
 The company's R&D department is headed by Dr. C. Sankar Rao who has
 over 31 years experience in drug and pharmaceutical R&D including 25
 years in Indian Drugs and Pharmaceuticals Ltd. (IDPL). 
 
 The Company had entered into an agreement with Indian Institute of
 Chemical Technology (IICT), Hyderabad for process know-how for the
 manufacture of 2 of its products Ketorolac Tromethamine and Enalapril
 Maleate on  2nd December 1992.
 
 Neuland Drugs & Pharmaceuticals Private Limited (NDPL), a company set
 up by the promoters to manufacture bulk drugs, was incorporated in
 1988 and merged with Neuland Laboratories Limited, with effect from
 April 1, 1992 as per the Scheme of Amalgamation approved by the High
 Court of
 Andhra Pradesh on April 6, 1993.  As per the scheme, one fully paid
 up equity share in Neuland Laboratories Limited was exchanged for
 every seven fully paid up equity shares held in NDPL ranking
 pari-passu with the existing shares of Neuland.
 
 2009
 
 - Neuland Laboratories Ltd has informed that Ms. Deepika Gupta has
 joined us as Company Secretary on 13th May 2009 and she will also act
 as compliance officer of the Company from 13th May 2009 onwards in
 place of Mr. A. Raghvendracharyulu.
 
 2012
 -Neuland Laboratories Ltd Issues Rights in the Ratio of 5:12
 
 --Registered Office of the Company has been shifted to Sanali Info
 park, 'A' Block, Ground floor,8-2-120/113, Road No.2, Banajara Hills,
 Hyderabad- 500034 from 204, Meridian plaza 6-3-953/1, Ameerpet,
 Hyderabad- 500016.
 
 2013
 
 - Board has recommended a Dividend of Rs. 1.20 per share of a face
 value of Rs. 10 each.
 - Neuland Labs Track Record of cGMP Excellence complemented by 2013
 CMO Leadership Award for Regulatory Excellence.
 
 2014
 
 - Neuland Labs Inaugurates new manufacturing facility constructed for
 its Collaboration with Mitsubishi Healthcare Unit API Corporation.
 - Board has recommended a Dividend of 30% (including a special
 dividend of 15%) at Rs. 3 per equity share on a face value of Rs. 10
 each,
 -Neuland Laboratories has announced  Rights in the Ratio of  4:25
 
 2016
 -Company has entered into a Joint Development Agreement (JDA) with
 Phoenix Embassy Techno Zone Private Limited.
                                                   
स्रोत: रेलीगरे टेचनोवा

न्यूज़ फ़्लैश

  • BREAKING NEWS RED : हरियाणा में शाम 6 बजे तक 62.14% मतदान
  • BREAKING NEWS RED : महाराष्ट्र में शाम 6 बजे तक 55.58% मतदान
  • ELECTION FLASH : हरियाणा में BJP का क्लीन स्वीप
  • ELECTION FLASH : हरियाणा:BJP को तीन चौथाई सीट मिलने की उम्मीद
  • ELECTION FLASH : हरियाणा: BJP-75 सीट, कांग्रेस-10 सीट
  • ELECTION FLASH : हरियाणा: INLD-0, अकाली दल-1 सीट
  • ELECTION FLASH : हरियाणा: JJP-2 सीट, अन्य-2 सीट
  • ELECTION FLASH : महाराष्ट्र: BJP-सेना गठबंधन की जबरदस्त जीत
  • ELECTION FLASH : BJP-शिवसेना को 243 सीटें मिलने की उम्मीद
  • ELECTION FLASH : महाराष्ट्र:BJP-141 सीट, शिवसेना-102 सीट

अभी देखें

ओवरड्राइव

OUR WINNING PICKS

DID YOU INVEST?

INTRADAY PICKS!

(August 06, 2018)

AT (Rs)



GAIN (Rs)

ALL TIME WINNERS

RECO PRICE

PEAK PRICE

OUR PACKAGES

Super Combo

Powerful mix of both trader and investor packs with timely expert advice.

Technical

Designed especially for traders looking to tap the profit opportunities of volatile markets.

Fundamental

For all investors looking to unearth stocks that are poised to move.